User login
Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner published monthly since 1965. Concise clinical articles present the practical side of dermatology, helping physicians to improve patient care. Cutis is referenced in Index Medicus/MEDLINE and is written and edited by industry leaders.
ass lick
assault rifle
balls
ballsac
black jack
bleach
Boko Haram
bondage
causas
cheap
child abuse
cocaine
compulsive behaviors
cost of miracles
cunt
Daech
display network stats
drug paraphernalia
explosion
fart
fda and death
fda AND warn
fda AND warning
fda AND warns
feom
fuck
gambling
gfc
gun
human trafficking
humira AND expensive
illegal
ISIL
ISIS
Islamic caliphate
Islamic state
madvocate
masturbation
mixed martial arts
MMA
molestation
national rifle association
NRA
nsfw
nuccitelli
pedophile
pedophilia
poker
porn
porn
pornography
psychedelic drug
recreational drug
sex slave rings
shit
slot machine
snort
substance abuse
terrorism
terrorist
texarkana
Texas hold 'em
UFC
section[contains(@class, 'nav-hidden')]
section[contains(@class, 'nav-hidden active')
A peer-reviewed, indexed journal for dermatologists with original research, image quizzes, cases and reviews, and columns.
Systemic Mastocytosis: Classification, Pathogenesis, Diagnosis, and Treatment
Case Report
A 46-year-old woman presented with a rash that had been present for more than 20 years but had progressed over the past 6 years and was associated with pruritus, burning, and blistering precipitated by temperature changes or anxiety. In addition, she had watery diarrhea for 5 years and also had been found to have osteopenia. She was a healthy-appearing woman with prominent facial erythema. Vital signs were normal. Skin examination revealed facial telangiectases as well as erythema and 2- to 4-mm reddish brown papules and macules on the extensor surfaces of the arms and thighs, chest, abdomen, and back, coalescing into plaques on the thighs (Figure). She had bilateral axillary lymphadenopathy. Liver and spleen were not palpable. Her hemoglobin level was 12.7 g/dL (reference range, 14.0–17.5 g/dL); white blood cell count was 5.2X109/L (reference range, 4.5–11.0X109/L) with 63 neutrophils, 36 lymphocytes, and 1 monocyte; and platelet count was 301X109/L (reference range, 150–350X109/L). Chemistries were within reference range, except for an alkaline phosphatase level of 136 U/L (reference range, 38–126 U/L). Biopsy of a forearm skin lesion showed an unremarkable epidermal layer overlying a dermis without vasculitis but with a mild increase in perivascular and focally interstitial mononuclear cells staining with mast cell tryptase and CD117. Serum tryptase level was greater than 200 ng/mL (reference,
- Mekori YA, Metcalfe DD. Mast cell-T cell interactions. J Allergy Clin Immunol. 1999;104(3, pt 1):517-523.
- Weller K, Foitzik K, Paus R, et al. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006;20:2366-2368. Epub September 11, 2006.
- Nienartowicz A, Sobaniec-Lotowska ME, Jarocka-Cyrta E, et al. Mast cells in neoangiogenesis. Med Sci Monit. 2006;12:RA53-56. Epub February 23, 2006.
- Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46:35-48.
- The World Health Organization. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Vol 3. IARC Press: Lyon, France; 2001:293-302.
- Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519-528.
- Valent P, Akin C, Sperr WR, et al. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003;17:1227-1241.
- Stankovic K, Sarrot-Reynauld F, Puget M, et al. Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease. Eur J Intern Med. 2005;16:387-390.
- Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol. 2003;27:1013-1019.
- Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001;98:3784-3792.
- Metcalfe DD. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc. 2005;116:185-203.
- Mickys U, Barakauskiene A, Wolf-Peeters D, et al. Aggressive systemic mastocytosis complicated by protein-losing enteropathy. Dig Liver Dis. 2007;39:693-697. Epub July 14, 2006.
- Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am. 2000;14:579-623.
- Horny HP, Kaiserling E, Campbell M, et al. Liver findings in generalized mastocytosis. a clinicopathologic study. Cancer. 1989;63:532-538.
- Webb TA, Li CY, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer. 1982;49:927-938.
- Chen CC, Andrich MP, Mican JM, et al. A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med. 1994;35:1471-1475.
- van Toorenenbergen AW, Oranje AP. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin Chim Acta. 2005;359(1-2):72-77.
- Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85: 852-855.
- Friedman B, Darling G, Norton J, et al. Splenectomy in the management of systemic mast cell disease. Surgery. 1990;107:94-100.
- Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006;107:1429-1439.
- Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.
- Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270-4276. Epub August 21, 2003.
- Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. C
Case Report
A 46-year-old woman presented with a rash that had been present for more than 20 years but had progressed over the past 6 years and was associated with pruritus, burning, and blistering precipitated by temperature changes or anxiety. In addition, she had watery diarrhea for 5 years and also had been found to have osteopenia. She was a healthy-appearing woman with prominent facial erythema. Vital signs were normal. Skin examination revealed facial telangiectases as well as erythema and 2- to 4-mm reddish brown papules and macules on the extensor surfaces of the arms and thighs, chest, abdomen, and back, coalescing into plaques on the thighs (Figure). She had bilateral axillary lymphadenopathy. Liver and spleen were not palpable. Her hemoglobin level was 12.7 g/dL (reference range, 14.0–17.5 g/dL); white blood cell count was 5.2X109/L (reference range, 4.5–11.0X109/L) with 63 neutrophils, 36 lymphocytes, and 1 monocyte; and platelet count was 301X109/L (reference range, 150–350X109/L). Chemistries were within reference range, except for an alkaline phosphatase level of 136 U/L (reference range, 38–126 U/L). Biopsy of a forearm skin lesion showed an unremarkable epidermal layer overlying a dermis without vasculitis but with a mild increase in perivascular and focally interstitial mononuclear cells staining with mast cell tryptase and CD117. Serum tryptase level was greater than 200 ng/mL (reference,
Case Report
A 46-year-old woman presented with a rash that had been present for more than 20 years but had progressed over the past 6 years and was associated with pruritus, burning, and blistering precipitated by temperature changes or anxiety. In addition, she had watery diarrhea for 5 years and also had been found to have osteopenia. She was a healthy-appearing woman with prominent facial erythema. Vital signs were normal. Skin examination revealed facial telangiectases as well as erythema and 2- to 4-mm reddish brown papules and macules on the extensor surfaces of the arms and thighs, chest, abdomen, and back, coalescing into plaques on the thighs (Figure). She had bilateral axillary lymphadenopathy. Liver and spleen were not palpable. Her hemoglobin level was 12.7 g/dL (reference range, 14.0–17.5 g/dL); white blood cell count was 5.2X109/L (reference range, 4.5–11.0X109/L) with 63 neutrophils, 36 lymphocytes, and 1 monocyte; and platelet count was 301X109/L (reference range, 150–350X109/L). Chemistries were within reference range, except for an alkaline phosphatase level of 136 U/L (reference range, 38–126 U/L). Biopsy of a forearm skin lesion showed an unremarkable epidermal layer overlying a dermis without vasculitis but with a mild increase in perivascular and focally interstitial mononuclear cells staining with mast cell tryptase and CD117. Serum tryptase level was greater than 200 ng/mL (reference,
- Mekori YA, Metcalfe DD. Mast cell-T cell interactions. J Allergy Clin Immunol. 1999;104(3, pt 1):517-523.
- Weller K, Foitzik K, Paus R, et al. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006;20:2366-2368. Epub September 11, 2006.
- Nienartowicz A, Sobaniec-Lotowska ME, Jarocka-Cyrta E, et al. Mast cells in neoangiogenesis. Med Sci Monit. 2006;12:RA53-56. Epub February 23, 2006.
- Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46:35-48.
- The World Health Organization. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Vol 3. IARC Press: Lyon, France; 2001:293-302.
- Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519-528.
- Valent P, Akin C, Sperr WR, et al. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003;17:1227-1241.
- Stankovic K, Sarrot-Reynauld F, Puget M, et al. Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease. Eur J Intern Med. 2005;16:387-390.
- Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol. 2003;27:1013-1019.
- Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001;98:3784-3792.
- Metcalfe DD. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc. 2005;116:185-203.
- Mickys U, Barakauskiene A, Wolf-Peeters D, et al. Aggressive systemic mastocytosis complicated by protein-losing enteropathy. Dig Liver Dis. 2007;39:693-697. Epub July 14, 2006.
- Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am. 2000;14:579-623.
- Horny HP, Kaiserling E, Campbell M, et al. Liver findings in generalized mastocytosis. a clinicopathologic study. Cancer. 1989;63:532-538.
- Webb TA, Li CY, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer. 1982;49:927-938.
- Chen CC, Andrich MP, Mican JM, et al. A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med. 1994;35:1471-1475.
- van Toorenenbergen AW, Oranje AP. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin Chim Acta. 2005;359(1-2):72-77.
- Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85: 852-855.
- Friedman B, Darling G, Norton J, et al. Splenectomy in the management of systemic mast cell disease. Surgery. 1990;107:94-100.
- Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006;107:1429-1439.
- Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.
- Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270-4276. Epub August 21, 2003.
- Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. C
- Mekori YA, Metcalfe DD. Mast cell-T cell interactions. J Allergy Clin Immunol. 1999;104(3, pt 1):517-523.
- Weller K, Foitzik K, Paus R, et al. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006;20:2366-2368. Epub September 11, 2006.
- Nienartowicz A, Sobaniec-Lotowska ME, Jarocka-Cyrta E, et al. Mast cells in neoangiogenesis. Med Sci Monit. 2006;12:RA53-56. Epub February 23, 2006.
- Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46:35-48.
- The World Health Organization. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, et al, eds. WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Vol 3. IARC Press: Lyon, France; 2001:293-302.
- Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519-528.
- Valent P, Akin C, Sperr WR, et al. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am. 2003;17:1227-1241.
- Stankovic K, Sarrot-Reynauld F, Puget M, et al. Systemic mastocytosis: predictable factors of poor prognosis present at the onset of the disease. Eur J Intern Med. 2005;16:387-390.
- Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol. 2003;27:1013-1019.
- Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood. 2001;98:3784-3792.
- Metcalfe DD. Regulation of normal and neoplastic human mast cell development in mastocytosis. Trans Am Clin Climatol Assoc. 2005;116:185-203.
- Mickys U, Barakauskiene A, Wolf-Peeters D, et al. Aggressive systemic mastocytosis complicated by protein-losing enteropathy. Dig Liver Dis. 2007;39:693-697. Epub July 14, 2006.
- Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am. 2000;14:579-623.
- Horny HP, Kaiserling E, Campbell M, et al. Liver findings in generalized mastocytosis. a clinicopathologic study. Cancer. 1989;63:532-538.
- Webb TA, Li CY, Yam LT. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer. 1982;49:927-938.
- Chen CC, Andrich MP, Mican JM, et al. A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med. 1994;35:1471-1475.
- van Toorenenbergen AW, Oranje AP. Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis. Clin Chim Acta. 2005;359(1-2):72-77.
- Horan RF, Sheffer AL, Austen KF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol. 1990;85: 852-855.
- Friedman B, Darling G, Norton J, et al. Splenectomy in the management of systemic mast cell disease. Surgery. 1990;107:94-100.
- Quintas-Cardama A, Aribi A, Cortes J, et al. Novel approaches in the treatment of systemic mastocytosis. Cancer. 2006;107:1429-1439.
- Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol. 2002;119:1090-1097.
- Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood. 2003;102:4270-4276. Epub August 21, 2003.
- Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. C
Glomangioma: A Case Report and Review of the Literature
Case Report
A 69-year-old man with a medical history of psoriasis and hypertension presented with an incidental finding of multiple asymptomatic, noncompressible, blue lesions over his arms, chest, and back. The lesions were present since childhood and had never been subject to a workup. He had no history of gastrointestinal bleeding and no known family history of similar lesions. His medications included amlodipine besylate, efalizumab, and valsartan. Physical examination revealed multiple nontender, blue, subcutaneous nodules that were 1 to 2 cm in diameter and located on the bilateral arms, chest, and back (Figure 1). A punch biopsy was performed from the chest lesions. Histopathologic examination revealed dilated vascular channels (Figure 2) that were positive for endothelial factor VIII and CD34 and surrounded by glomus cells positive for smooth muscle actin (Figure 3). The diagnosis of glomangioma was made and no further treatment was indicated.
Comment
Glomangiomas are benign localized tumors of the skin characterized by abnormal, smooth muscle–like glomus cells.1 In 1924, Masson2 described the neuromyoarterial glomus, which he later renamed the neurovascular glomus, and its tumors. The term glomangioma was coined by Bailey3 in 1935 and is currently applied to lesions with a wide vascular lumen, which are most commonly found in patients with multiple tumors.4 Glomus tumors arise from modified smooth muscle cells normally found in specialized arteriovenous shunts present in acral sites, especially the fingertips. This location reflects their function, as the arteriovenous anastomoses of these areas, also known as the Sucquet-Hoyer canals, are involved in temperature regulation. Sucquet-Hoyer canals are lined with endothelial cells, contain several layers of glomus cells in their walls, and connect afferent arterioles to efferent venules.5 Glomus tumors are thought to be hamartomas6 and account for 1% to 2% of all soft tissue tumors.5 There are 2 forms of glomus tumors, with the more common solitary variant accounting for 90% of cases and a more rare multiple variant, termed glomangioma, accounting for 10% of cases.7 The tumors of the solitary variant are small, painful, purple nodules with predilection for acral areas of the extremities, especially the nail beds of the fingers and toes.8 Aching pain, well-localized tenderness, and temperature sensitivity are the characteristic triad of signs and symptoms.5 They typically are less than 1 cm in diameter.8 In contrast, multiple glomus tumors are characterized as glomangiomas because of the angiomatous appearance of the lesions. Glomangiomas often appear during childhood as small bluish nodules situated deep in the dermis, widely scattered over the skin surface. They are rarely subungual and are less likely to be painful.8 Glomangiomas have a predilection for the upper extremities and occasionally are found on the lower extremities, head, and back. They may be slightly larger and less well-circumscribed than solitary glomus tumors.5 An autosomal dominant inheritance pattern has been described for glomus tumors, with some types being mapped to band 11q23.6 Familial cases have been reported with incomplete penetrance and variable expression.7 Glomangiomas have a male predominance, while females more frequently (in 70% of cases) are found to have solitary glomus tumors.5 Histopathologically, glomus tumors contain dilated vascular channels surrounded by glomus cells. The glomus cells are monomorphic round or polygonal cells with plump nuclei and scant eosinophilic cytoplasm. They are positive for smooth muscle actin, while vascular endothelium is positive for factor VIII and CD34.9 Choosing the appropriate treatment regimen for glomus tumors and glomangiomas should be individualized to the patient and guided by the clinical presentation. Treatment is not always indicated, particularly in asymptomatic cases of glomangioma. Surgical intervention, when needed, typically is excision with primary closure. Laser treatment, electromagnetic radiation, and sclerotherapy also have been used.5 Blue Rubber Bleb Nevus Syndrome—It is important to distinguish glomangioma from blue rubber bleb nevus syndrome (BRBNS), which is associated with venous malformations on both the skin and gastrointestinal tract. The BRBNS venous malformations of the gastrointestinal tract can be associated with clinically significant gastrointestinal bleeding.10 Lesions of BRBNS can be macular, papular, or nodular, and usually are multiple, varying in diameter from a few millimeters to several centimeters. The cutaneous lesions usually are asymptomatic and the overlying skin may show increased sweating. These lesions may appear at birth or in early childhood, and they tend to increase in size and frequency with age. Although they may occur anywhere, they are principally located on the upper limbs, trunk, and perineum. Acral lesions are unusual and the lesions have no evidence of malignant change.11 Cutaneous lesions of BRBNS are blue, soft, and nipplelike, easily compressing and refilling slowly.12 On the other hand, glomangiomas are noted for a distinct raised, often hyperkeratotic, cobblestonelike appearance, and could not be completely emptied by compression.13 Glomangiomas generally do not extend into deep structures.14 Histologically, glomangiomas contain clusters of dilated vascular channels lined by a thin layer of endothelial cells in the dermis or subcutaneous fat. The walls are a fibrous stroma, occasionally containing smooth muscle.12 Dilated vascular channels lined by endothelial cells are characteristic of both diseases. Therefore, biopsy results confirming the presence of glomus cells lining the dilated vascular channels characterize glomangiomas.10 back to top
- Parsi K, Kossard S. Multiple hereditary glomangiomas: successful treatment with sclerotherapy. Aust J Dermatol. 2002;43:43-47.
- Masson P. Le glomus neuromyo-artériel des régions tactiles et ses tumeurs. Lyon Chir. 1924;21:257-280.
- Bailey OT. The cutaneous glomus and its tumors—glomangiomas. Am J Pathol. 1935;11:915-936.
- Monteagudo C, Carda C, Llombart-Bosch A, et al. Multiple glomangiomyoma versus glomangioma: conceptual and ultrastructural observations. Am J Dermatopathol. 2000;22:371-373.
- Myers RS, Lo AK, Pawel BR. The glomangioma in the differential diagnosis of vascular malformations. Ann Plast Surg. 2006;57:443-446.
- Blume-Peytavi U, Adler YD, Geilen CC, et al. Multiple familial cutaneous glomangioma: a pedigree of 4 generations and critical analysis of histologic and genetic differences of glomus tumors. J Am Acad Dermatol. 2000;42:633-639.
- Chatterjee JS, Youssef AHK, Brown RM, et al. Congenital nodular multiple glomangioma: a case report. J Clin Pathol. 2005;58:102-103.
- Requena L, Galvan C, Sanchez Yus E, et al. Solitary plaque-like telangiectatic glomangioma. Br J Dermatol. 1998;139:902-905.
- Abou Jaoude JF, Roula Farah A, Sargi Z, et al. Glomus tumors: report on eleven cases and a review of the literature. Chir Main. 2000;19:243-252.
- Lu R, Krathen RA, Sanchez RL, et al. Multiple glomangiomas: potential for confusion with blue rubber bleb nevus syndrome. J Am Acad Dermatol. 2005;52:731-732.
- Moodley M, Ramdial P. Blue rubber bleb nevus syndrome: case report and review of the literature. Pediatrics. 1993;92:160-162.
- Nahm WK, Moise S, Eichenfield LF, et al. Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentation. J Am Acad Dermatol. 2004;50:101-106.
- Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol. 2004;140:971-976.
- Vercellino N, Nozza P, Oddone M, et al. Large plaque-like glomuvenous malformation (glomangioma) simulating venous malformation. Clin Exp Dermatol. 2006;31:538-541.
Case Report
A 69-year-old man with a medical history of psoriasis and hypertension presented with an incidental finding of multiple asymptomatic, noncompressible, blue lesions over his arms, chest, and back. The lesions were present since childhood and had never been subject to a workup. He had no history of gastrointestinal bleeding and no known family history of similar lesions. His medications included amlodipine besylate, efalizumab, and valsartan. Physical examination revealed multiple nontender, blue, subcutaneous nodules that were 1 to 2 cm in diameter and located on the bilateral arms, chest, and back (Figure 1). A punch biopsy was performed from the chest lesions. Histopathologic examination revealed dilated vascular channels (Figure 2) that were positive for endothelial factor VIII and CD34 and surrounded by glomus cells positive for smooth muscle actin (Figure 3). The diagnosis of glomangioma was made and no further treatment was indicated.
Comment
Glomangiomas are benign localized tumors of the skin characterized by abnormal, smooth muscle–like glomus cells.1 In 1924, Masson2 described the neuromyoarterial glomus, which he later renamed the neurovascular glomus, and its tumors. The term glomangioma was coined by Bailey3 in 1935 and is currently applied to lesions with a wide vascular lumen, which are most commonly found in patients with multiple tumors.4 Glomus tumors arise from modified smooth muscle cells normally found in specialized arteriovenous shunts present in acral sites, especially the fingertips. This location reflects their function, as the arteriovenous anastomoses of these areas, also known as the Sucquet-Hoyer canals, are involved in temperature regulation. Sucquet-Hoyer canals are lined with endothelial cells, contain several layers of glomus cells in their walls, and connect afferent arterioles to efferent venules.5 Glomus tumors are thought to be hamartomas6 and account for 1% to 2% of all soft tissue tumors.5 There are 2 forms of glomus tumors, with the more common solitary variant accounting for 90% of cases and a more rare multiple variant, termed glomangioma, accounting for 10% of cases.7 The tumors of the solitary variant are small, painful, purple nodules with predilection for acral areas of the extremities, especially the nail beds of the fingers and toes.8 Aching pain, well-localized tenderness, and temperature sensitivity are the characteristic triad of signs and symptoms.5 They typically are less than 1 cm in diameter.8 In contrast, multiple glomus tumors are characterized as glomangiomas because of the angiomatous appearance of the lesions. Glomangiomas often appear during childhood as small bluish nodules situated deep in the dermis, widely scattered over the skin surface. They are rarely subungual and are less likely to be painful.8 Glomangiomas have a predilection for the upper extremities and occasionally are found on the lower extremities, head, and back. They may be slightly larger and less well-circumscribed than solitary glomus tumors.5 An autosomal dominant inheritance pattern has been described for glomus tumors, with some types being mapped to band 11q23.6 Familial cases have been reported with incomplete penetrance and variable expression.7 Glomangiomas have a male predominance, while females more frequently (in 70% of cases) are found to have solitary glomus tumors.5 Histopathologically, glomus tumors contain dilated vascular channels surrounded by glomus cells. The glomus cells are monomorphic round or polygonal cells with plump nuclei and scant eosinophilic cytoplasm. They are positive for smooth muscle actin, while vascular endothelium is positive for factor VIII and CD34.9 Choosing the appropriate treatment regimen for glomus tumors and glomangiomas should be individualized to the patient and guided by the clinical presentation. Treatment is not always indicated, particularly in asymptomatic cases of glomangioma. Surgical intervention, when needed, typically is excision with primary closure. Laser treatment, electromagnetic radiation, and sclerotherapy also have been used.5 Blue Rubber Bleb Nevus Syndrome—It is important to distinguish glomangioma from blue rubber bleb nevus syndrome (BRBNS), which is associated with venous malformations on both the skin and gastrointestinal tract. The BRBNS venous malformations of the gastrointestinal tract can be associated with clinically significant gastrointestinal bleeding.10 Lesions of BRBNS can be macular, papular, or nodular, and usually are multiple, varying in diameter from a few millimeters to several centimeters. The cutaneous lesions usually are asymptomatic and the overlying skin may show increased sweating. These lesions may appear at birth or in early childhood, and they tend to increase in size and frequency with age. Although they may occur anywhere, they are principally located on the upper limbs, trunk, and perineum. Acral lesions are unusual and the lesions have no evidence of malignant change.11 Cutaneous lesions of BRBNS are blue, soft, and nipplelike, easily compressing and refilling slowly.12 On the other hand, glomangiomas are noted for a distinct raised, often hyperkeratotic, cobblestonelike appearance, and could not be completely emptied by compression.13 Glomangiomas generally do not extend into deep structures.14 Histologically, glomangiomas contain clusters of dilated vascular channels lined by a thin layer of endothelial cells in the dermis or subcutaneous fat. The walls are a fibrous stroma, occasionally containing smooth muscle.12 Dilated vascular channels lined by endothelial cells are characteristic of both diseases. Therefore, biopsy results confirming the presence of glomus cells lining the dilated vascular channels characterize glomangiomas.10 back to top
Case Report
A 69-year-old man with a medical history of psoriasis and hypertension presented with an incidental finding of multiple asymptomatic, noncompressible, blue lesions over his arms, chest, and back. The lesions were present since childhood and had never been subject to a workup. He had no history of gastrointestinal bleeding and no known family history of similar lesions. His medications included amlodipine besylate, efalizumab, and valsartan. Physical examination revealed multiple nontender, blue, subcutaneous nodules that were 1 to 2 cm in diameter and located on the bilateral arms, chest, and back (Figure 1). A punch biopsy was performed from the chest lesions. Histopathologic examination revealed dilated vascular channels (Figure 2) that were positive for endothelial factor VIII and CD34 and surrounded by glomus cells positive for smooth muscle actin (Figure 3). The diagnosis of glomangioma was made and no further treatment was indicated.
Comment
Glomangiomas are benign localized tumors of the skin characterized by abnormal, smooth muscle–like glomus cells.1 In 1924, Masson2 described the neuromyoarterial glomus, which he later renamed the neurovascular glomus, and its tumors. The term glomangioma was coined by Bailey3 in 1935 and is currently applied to lesions with a wide vascular lumen, which are most commonly found in patients with multiple tumors.4 Glomus tumors arise from modified smooth muscle cells normally found in specialized arteriovenous shunts present in acral sites, especially the fingertips. This location reflects their function, as the arteriovenous anastomoses of these areas, also known as the Sucquet-Hoyer canals, are involved in temperature regulation. Sucquet-Hoyer canals are lined with endothelial cells, contain several layers of glomus cells in their walls, and connect afferent arterioles to efferent venules.5 Glomus tumors are thought to be hamartomas6 and account for 1% to 2% of all soft tissue tumors.5 There are 2 forms of glomus tumors, with the more common solitary variant accounting for 90% of cases and a more rare multiple variant, termed glomangioma, accounting for 10% of cases.7 The tumors of the solitary variant are small, painful, purple nodules with predilection for acral areas of the extremities, especially the nail beds of the fingers and toes.8 Aching pain, well-localized tenderness, and temperature sensitivity are the characteristic triad of signs and symptoms.5 They typically are less than 1 cm in diameter.8 In contrast, multiple glomus tumors are characterized as glomangiomas because of the angiomatous appearance of the lesions. Glomangiomas often appear during childhood as small bluish nodules situated deep in the dermis, widely scattered over the skin surface. They are rarely subungual and are less likely to be painful.8 Glomangiomas have a predilection for the upper extremities and occasionally are found on the lower extremities, head, and back. They may be slightly larger and less well-circumscribed than solitary glomus tumors.5 An autosomal dominant inheritance pattern has been described for glomus tumors, with some types being mapped to band 11q23.6 Familial cases have been reported with incomplete penetrance and variable expression.7 Glomangiomas have a male predominance, while females more frequently (in 70% of cases) are found to have solitary glomus tumors.5 Histopathologically, glomus tumors contain dilated vascular channels surrounded by glomus cells. The glomus cells are monomorphic round or polygonal cells with plump nuclei and scant eosinophilic cytoplasm. They are positive for smooth muscle actin, while vascular endothelium is positive for factor VIII and CD34.9 Choosing the appropriate treatment regimen for glomus tumors and glomangiomas should be individualized to the patient and guided by the clinical presentation. Treatment is not always indicated, particularly in asymptomatic cases of glomangioma. Surgical intervention, when needed, typically is excision with primary closure. Laser treatment, electromagnetic radiation, and sclerotherapy also have been used.5 Blue Rubber Bleb Nevus Syndrome—It is important to distinguish glomangioma from blue rubber bleb nevus syndrome (BRBNS), which is associated with venous malformations on both the skin and gastrointestinal tract. The BRBNS venous malformations of the gastrointestinal tract can be associated with clinically significant gastrointestinal bleeding.10 Lesions of BRBNS can be macular, papular, or nodular, and usually are multiple, varying in diameter from a few millimeters to several centimeters. The cutaneous lesions usually are asymptomatic and the overlying skin may show increased sweating. These lesions may appear at birth or in early childhood, and they tend to increase in size and frequency with age. Although they may occur anywhere, they are principally located on the upper limbs, trunk, and perineum. Acral lesions are unusual and the lesions have no evidence of malignant change.11 Cutaneous lesions of BRBNS are blue, soft, and nipplelike, easily compressing and refilling slowly.12 On the other hand, glomangiomas are noted for a distinct raised, often hyperkeratotic, cobblestonelike appearance, and could not be completely emptied by compression.13 Glomangiomas generally do not extend into deep structures.14 Histologically, glomangiomas contain clusters of dilated vascular channels lined by a thin layer of endothelial cells in the dermis or subcutaneous fat. The walls are a fibrous stroma, occasionally containing smooth muscle.12 Dilated vascular channels lined by endothelial cells are characteristic of both diseases. Therefore, biopsy results confirming the presence of glomus cells lining the dilated vascular channels characterize glomangiomas.10 back to top
- Parsi K, Kossard S. Multiple hereditary glomangiomas: successful treatment with sclerotherapy. Aust J Dermatol. 2002;43:43-47.
- Masson P. Le glomus neuromyo-artériel des régions tactiles et ses tumeurs. Lyon Chir. 1924;21:257-280.
- Bailey OT. The cutaneous glomus and its tumors—glomangiomas. Am J Pathol. 1935;11:915-936.
- Monteagudo C, Carda C, Llombart-Bosch A, et al. Multiple glomangiomyoma versus glomangioma: conceptual and ultrastructural observations. Am J Dermatopathol. 2000;22:371-373.
- Myers RS, Lo AK, Pawel BR. The glomangioma in the differential diagnosis of vascular malformations. Ann Plast Surg. 2006;57:443-446.
- Blume-Peytavi U, Adler YD, Geilen CC, et al. Multiple familial cutaneous glomangioma: a pedigree of 4 generations and critical analysis of histologic and genetic differences of glomus tumors. J Am Acad Dermatol. 2000;42:633-639.
- Chatterjee JS, Youssef AHK, Brown RM, et al. Congenital nodular multiple glomangioma: a case report. J Clin Pathol. 2005;58:102-103.
- Requena L, Galvan C, Sanchez Yus E, et al. Solitary plaque-like telangiectatic glomangioma. Br J Dermatol. 1998;139:902-905.
- Abou Jaoude JF, Roula Farah A, Sargi Z, et al. Glomus tumors: report on eleven cases and a review of the literature. Chir Main. 2000;19:243-252.
- Lu R, Krathen RA, Sanchez RL, et al. Multiple glomangiomas: potential for confusion with blue rubber bleb nevus syndrome. J Am Acad Dermatol. 2005;52:731-732.
- Moodley M, Ramdial P. Blue rubber bleb nevus syndrome: case report and review of the literature. Pediatrics. 1993;92:160-162.
- Nahm WK, Moise S, Eichenfield LF, et al. Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentation. J Am Acad Dermatol. 2004;50:101-106.
- Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol. 2004;140:971-976.
- Vercellino N, Nozza P, Oddone M, et al. Large plaque-like glomuvenous malformation (glomangioma) simulating venous malformation. Clin Exp Dermatol. 2006;31:538-541.
- Parsi K, Kossard S. Multiple hereditary glomangiomas: successful treatment with sclerotherapy. Aust J Dermatol. 2002;43:43-47.
- Masson P. Le glomus neuromyo-artériel des régions tactiles et ses tumeurs. Lyon Chir. 1924;21:257-280.
- Bailey OT. The cutaneous glomus and its tumors—glomangiomas. Am J Pathol. 1935;11:915-936.
- Monteagudo C, Carda C, Llombart-Bosch A, et al. Multiple glomangiomyoma versus glomangioma: conceptual and ultrastructural observations. Am J Dermatopathol. 2000;22:371-373.
- Myers RS, Lo AK, Pawel BR. The glomangioma in the differential diagnosis of vascular malformations. Ann Plast Surg. 2006;57:443-446.
- Blume-Peytavi U, Adler YD, Geilen CC, et al. Multiple familial cutaneous glomangioma: a pedigree of 4 generations and critical analysis of histologic and genetic differences of glomus tumors. J Am Acad Dermatol. 2000;42:633-639.
- Chatterjee JS, Youssef AHK, Brown RM, et al. Congenital nodular multiple glomangioma: a case report. J Clin Pathol. 2005;58:102-103.
- Requena L, Galvan C, Sanchez Yus E, et al. Solitary plaque-like telangiectatic glomangioma. Br J Dermatol. 1998;139:902-905.
- Abou Jaoude JF, Roula Farah A, Sargi Z, et al. Glomus tumors: report on eleven cases and a review of the literature. Chir Main. 2000;19:243-252.
- Lu R, Krathen RA, Sanchez RL, et al. Multiple glomangiomas: potential for confusion with blue rubber bleb nevus syndrome. J Am Acad Dermatol. 2005;52:731-732.
- Moodley M, Ramdial P. Blue rubber bleb nevus syndrome: case report and review of the literature. Pediatrics. 1993;92:160-162.
- Nahm WK, Moise S, Eichenfield LF, et al. Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentation. J Am Acad Dermatol. 2004;50:101-106.
- Boon LM, Mulliken JB, Enjolras O, et al. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol. 2004;140:971-976.
- Vercellino N, Nozza P, Oddone M, et al. Large plaque-like glomuvenous malformation (glomangioma) simulating venous malformation. Clin Exp Dermatol. 2006;31:538-541.